> top > docs > PMC:7228307 > spans > 41939-42656 > annotations

PMC:7228307 / 41939-42656 JSONTXT

Annnotations TAB JSON ListView MergeView

LitCovid-PubTator

Id Subject Object Predicate Lexical cue tao:has_database_id
714 225-233 Gene denotes FcγRIIIa Gene:2214
715 363-370 Gene denotes FcγRIIb Gene:2213
716 534-541 Gene denotes FcγRIII Gene:2214
717 577-585 Gene denotes FcγRIIIa Gene:2214
718 405-409 Gene denotes FcγR Gene:2213
719 206-210 Gene denotes FcγR Gene:2213
720 55-59 Gene denotes FcγR Gene:2213
721 645-652 Species denotes patient Tax:9606
722 292-297 Disease denotes tumor MESH:D009369
723 710-716 Disease denotes cancer MESH:D009369

LitCovid-PD-FMA-UBERON

Id Subject Object Predicate Lexical cue fma_id
T359 298-303 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646

LitCovid-PD-MONDO

Id Subject Object Predicate Lexical cue mondo_id
T68 267-271 Disease denotes ADCC http://purl.obolibrary.org/obo/MONDO_0008734
T69 292-297 Disease denotes tumor http://purl.obolibrary.org/obo/MONDO_0005070
T70 710-716 Disease denotes cancer http://purl.obolibrary.org/obo/MONDO_0004992

LitCovid-PD-CLO

Id Subject Object Predicate Lexical cue
T753 55-57 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T754 129-139 http://purl.obolibrary.org/obo/CLO_0001658 denotes activation
T755 190-200 http://purl.obolibrary.org/obo/CLO_0001658 denotes activating
T756 206-208 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T757 225-227 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T758 298-303 http://purl.obolibrary.org/obo/GO_0005623 denotes cells
T759 363-365 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T760 405-407 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T761 410-411 http://purl.obolibrary.org/obo/CLO_0001020 denotes A
T762 534-536 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T763 559-561 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T764 577-579 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc

LitCovid-PD-CHEBI

Id Subject Object Predicate Lexical cue chebi_id
T218 60-68 Chemical denotes effector http://purl.obolibrary.org/obo/CHEBI_35224

LitCovid-sample-PD-IDO

Id Subject Object Predicate Lexical cue
T212 298-303 http://purl.obolibrary.org/obo/CL_0000000 denotes cells

LitCovid-sample-Pubtator

Id Subject Object Predicate Lexical cue pubann:denotes
714 225-233 Gene denotes FcγRIIIa Gene:2214
715 363-370 Gene denotes FcγRIIb Gene:2213
716 534-541 Gene denotes FcγRIII Gene:2214
717 577-585 Gene denotes FcγRIIIa Gene:2214
718 405-409 Gene denotes FcγR Gene:2213
719 206-210 Gene denotes FcγR Gene:2213
720 55-59 Gene denotes FcγR Gene:2213
721 645-652 Species denotes patient Tax:9606
722 292-297 Disease denotes tumor MESH:D009369
723 710-716 Disease denotes cancer MESH:D009369

LitCovid-sample-sentences

Id Subject Object Predicate Lexical cue
T235 0-111 Sentence denotes Thus, the challenge for the development of more potent FcγR effector mAbs is to overcome three major obstacles.
T236 112-304 Sentence denotes First, improving activation potency by selectively enhancing interaction with activating‐type FcγR, particularly FcγRIIIa owing to its predominant role in ADCC‐mediated killing of tumor cells.
T237 305-371 Sentence denotes Second, reducing binding interactions with the inhibitory FcγRIIb.
T238 372-446 Sentence denotes These two approaches improve the FcγR A‐to‐I ratio of cytotoxic IgG1 mAbs.
T239 447-717 Sentence denotes Third, overcoming the significant affinity difference in the interaction with the main FcγRIII allelic forms of FcγRIIIa‐V158 and FcγRIIIa‐F158 76, 83, 84 which appears to be an important source of patient variability in responses to therapeutic mAb treatment of cancer.

LitCovid-sample-PD-FMA

Id Subject Object Predicate Lexical cue fma_id
T358 298-303 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646

LitCovid-sample-PD-GO-BP-0

Id Subject Object Predicate Lexical cue
T106 267-271 http://purl.obolibrary.org/obo/GO_0001788 denotes ADCC

LitCovid-sample-PD-MONDO

Id Subject Object Predicate Lexical cue mondo_id
T25 292-297 Disease denotes tumor http://purl.obolibrary.org/obo/MONDO_0005070
T26 710-716 Disease denotes cancer http://purl.obolibrary.org/obo/MONDO_0004992

LitCovid-sample-PD-HP

Id Subject Object Predicate Lexical cue hp_id
T15 292-297 Phenotype denotes tumor http://purl.obolibrary.org/obo/HP_0002664
T16 710-716 Phenotype denotes cancer http://purl.obolibrary.org/obo/HP_0002664

LitCovid-sample-GO-BP

Id Subject Object Predicate Lexical cue
T106 267-271 http://purl.obolibrary.org/obo/GO_0001788 denotes ADCC

LitCovid-PD-GO-BP

Id Subject Object Predicate Lexical cue
T106 267-271 http://purl.obolibrary.org/obo/GO_0001788 denotes ADCC

LitCovid-sentences

Id Subject Object Predicate Lexical cue
T235 0-111 Sentence denotes Thus, the challenge for the development of more potent FcγR effector mAbs is to overcome three major obstacles.
T236 112-304 Sentence denotes First, improving activation potency by selectively enhancing interaction with activating‐type FcγR, particularly FcγRIIIa owing to its predominant role in ADCC‐mediated killing of tumor cells.
T237 305-371 Sentence denotes Second, reducing binding interactions with the inhibitory FcγRIIb.
T238 372-446 Sentence denotes These two approaches improve the FcγR A‐to‐I ratio of cytotoxic IgG1 mAbs.
T239 447-717 Sentence denotes Third, overcoming the significant affinity difference in the interaction with the main FcγRIII allelic forms of FcγRIIIa‐V158 and FcγRIIIa‐F158 76, 83, 84 which appears to be an important source of patient variability in responses to therapeutic mAb treatment of cancer.

LitCovid-PD-HP

Id Subject Object Predicate Lexical cue hp_id
T15 292-297 Phenotype denotes tumor http://purl.obolibrary.org/obo/HP_0002664
T16 710-716 Phenotype denotes cancer http://purl.obolibrary.org/obo/HP_0002664